Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors ...
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms...
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated...
If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease ...
Plaintiffs’ attorneys celebrate massive antitrust win against rising pharmaceutical costs
Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three...
FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance ...
Barchart Research What to Expect from TAK Earnings TAK Generated May 12, 2026 Current Price $16.42 EPS Estimate $$0.21 Consensus Rating Moderate Buy Average Move 3.15% Can Takeda's Pipeline Progress Finally...
Monday U.S. Economic Lookahead Existing home sales (April) Featured Earnings ...
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients